PL324091A1 - Compositions and procedure for treating sclerosis multiplex - Google Patents

Compositions and procedure for treating sclerosis multiplex

Info

Publication number
PL324091A1
PL324091A1 PL95324091A PL32409195A PL324091A1 PL 324091 A1 PL324091 A1 PL 324091A1 PL 95324091 A PL95324091 A PL 95324091A PL 32409195 A PL32409195 A PL 32409195A PL 324091 A1 PL324091 A1 PL 324091A1
Authority
PL
Poland
Prior art keywords
compositions
procedure
sclerosis multiplex
treating sclerosis
treating
Prior art date
Application number
PL95324091A
Inventor
Dawn Smilek
Michael Samson
Malcolm Gefter
Di-Hwei Hsu
Jia-Dong Shi
Xavier Paliard
Brigitte Devaux
Jonathan Rothbard
Henry Franzen
Original Assignee
Immulogic Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharma Corp filed Critical Immulogic Pharma Corp
Publication of PL324091A1 publication Critical patent/PL324091A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
PL95324091A 1994-10-25 1995-10-25 Compositions and procedure for treating sclerosis multiplex PL324091A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32822494A 1994-10-25 1994-10-25
US40422895A 1995-03-15 1995-03-15

Publications (1)

Publication Number Publication Date
PL324091A1 true PL324091A1 (en) 1998-05-11

Family

ID=26986277

Family Applications (1)

Application Number Title Priority Date Filing Date
PL95324091A PL324091A1 (en) 1994-10-25 1995-10-25 Compositions and procedure for treating sclerosis multiplex

Country Status (15)

Country Link
EP (1) EP0787147A1 (en)
JP (1) JPH10504039A (en)
AU (1) AU4278296A (en)
BR (1) BR9509438A (en)
CA (1) CA2203629A1 (en)
CZ (1) CZ122697A3 (en)
FI (1) FI971750A (en)
HU (1) HUT77047A (en)
IL (1) IL115766A0 (en)
IS (1) IS4466A (en)
NO (1) NO971900L (en)
PL (1) PL324091A1 (en)
SI (1) SI9520118A (en)
SK (1) SK51297A3 (en)
WO (1) WO1996012737A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
ATE412175T1 (en) 1996-03-21 2008-11-15 Circassia Ltd USE OF CRYPTIC PEPTIDES TO INDUCE IMMUNOLOGICAL TOLERANCE
CA2263730A1 (en) * 1996-08-15 1998-02-19 Agrivax Incorporated Delivery of tolerogenic antigens via edible plants or plant-derived products
CA2201841C (en) * 1997-04-04 2010-01-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
SE9703287D0 (en) * 1997-09-11 1997-09-11 Astra Ab Peptides
CA2330826A1 (en) * 1998-05-05 1999-11-11 Corixa Corporation Myelin basic protein peptides and uses thereof
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
JP2003532618A (en) * 1998-05-19 2003-11-05 イエダ リサーチ アンド デベロプメント カンパニイ リミテッド Cells, nervous system-specific antigens and their uses
EP1288226A1 (en) * 2001-09-03 2003-03-05 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Modification of the expression levels of Toll-like receptor familiy members for influencing neurodegeneration and neuroprotection in the human central nervous system
GB0202399D0 (en) * 2002-02-01 2002-03-20 Univ Bristol Peptide
AU2003219432B2 (en) 2002-03-27 2010-04-01 Pharmascience Inc. Antisense IAP nucleobase oligomers and uses thereof
DE10230381A1 (en) 2002-07-05 2004-01-22 Institut für Medizintechnologie Magdeburg GmbH, IMTM Use of inhibitors of alanyl aminopeptidases and pharmaceutical compositions comprising them
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
EP2572734B1 (en) 2006-10-31 2016-04-06 East Carolina University Cytokine-based fusion proteins for treatment of immune disorders
WO2010024927A2 (en) * 2008-08-28 2010-03-04 The Research Foundation Of State University Of New York Treatment of amyloidoses using myelin basic protein and fragments thereof
US20120082644A1 (en) 2009-03-31 2012-04-05 Mannie Mark D Cytokines and neuroantigens for treatment of immune disorders
KR20120103591A (en) 2009-10-12 2012-09-19 라이프바이오 라보라토리즈 엘엘씨 Composition for treatment of multiple sclerosis
RU2448685C2 (en) * 2009-11-30 2012-04-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Liposomes containing oligopeptides - fragments of myelin basic protein, pharmaceutical composition and method of treating multiple sclerosis
US8956878B2 (en) 2011-03-21 2015-02-17 Atlantic Cancer Research Institute Polypeptides with affinity for heat shock proteins (HSPS) and HSP associated complexes (HACS) and their use in diagnosis and therapy
CN106102835B (en) 2014-01-13 2020-11-03 博格有限责任公司 Enolase 1(ENO1) compositions and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1336954C (en) * 1987-06-24 1995-09-12 Howard L. Weiner Treatment of autoimmune diseases by oral administration of autoantigens
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
WO1991008760A1 (en) * 1989-12-20 1991-06-27 Brigham And Women's Hospital Improved treatment of autoimmune diseases by aerosol administration of auto antigens
AU651097B2 (en) * 1990-03-02 1994-07-14 Autoimmune, Inc. Enhancement of the down-regulation of autoimmune diseases by oral administration of autoantigens
IL165071A (en) * 1990-03-30 2008-06-05 Autoimmune Inc Peptide capable of stimulating a subgroup of t-cells from multiple sclerosis patients
CA2053799C (en) * 1991-10-22 2002-03-12 Kenneth G. Warren Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
AU3220693A (en) * 1991-11-19 1993-06-15 Anergen, Inc. Mhc subunit conjugates useful in ameliorating deleterious immune responses
KR950700082A (en) * 1992-02-28 1995-01-16 로버트 씨. 비숍 How to Treat Autoimmune Diseases by Bystander
IL105153A (en) * 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
IL105347A0 (en) * 1992-04-09 1993-08-18 Autoimmune Corp Multiple sclerosis t-cell receptor
WO1993025661A1 (en) * 1992-06-10 1993-12-23 President And Fellows Of Harvard College Heterogeneous proteolipid peptide 139-151-specific t cell clones
AU5080393A (en) * 1992-08-17 1994-03-15 Autoimmune, Inc. Bystander suppression of retroviral-associated neurological disease
CA2170901A1 (en) * 1993-09-03 1995-03-09 Brigitte Devaux Uses of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune disease
WO1995007096A1 (en) * 1993-09-06 1995-03-16 La Trobe University Treatment of autoimmune disease
JPH09502981A (en) * 1993-09-22 1997-03-25 ザ ボード オブ トラスティーズ フォー ザ リーランド スタンフォード ジュニア ユニバーシティ Interaction between T-cell receptor and antigen in autoimmune diseases
AU686797B2 (en) * 1994-04-08 1998-02-12 Brigham And Women's Hospital Treatment of autoimmune disease using oral tolerization and/or type I interferon
CA2187345A1 (en) * 1994-04-08 1995-10-19 Howard L. Weiner Treatment of autoimmune disease using oral tolerization and/or th2-enhancing cytokines
AU2470595A (en) * 1994-05-10 1995-11-29 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
ATE172304T1 (en) * 1994-06-09 1998-10-15 Tno ALPHA B CRYSTALLINE FOR USE IN DIAGNOSES AND THERAPY OF AUTOIMMUNE DISEASES, PARTICULARLY MULTIPLE SCERosis
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
EP1172376A1 (en) * 1994-11-18 2002-01-16 Neurocrine Biosciences, Inc. Peptide analogues at position 91 of human myelin basic protein for treatment of multiple sclerosis

Also Published As

Publication number Publication date
IS4466A (en) 1997-04-17
WO1996012737A2 (en) 1996-05-02
WO1996012737A3 (en) 1996-10-10
SI9520118A (en) 1998-08-31
NO971900L (en) 1997-06-25
BR9509438A (en) 1997-12-23
FI971750A (en) 1997-06-24
EP0787147A1 (en) 1997-08-06
HUT77047A (en) 1998-03-02
IL115766A0 (en) 1996-01-19
CZ122697A3 (en) 1997-09-17
FI971750A0 (en) 1997-04-24
AU4278296A (en) 1996-05-15
JPH10504039A (en) 1998-04-14
CA2203629A1 (en) 1996-05-02
SK51297A3 (en) 1998-03-04
NO971900D0 (en) 1997-04-24

Similar Documents

Publication Publication Date Title
PL324091A1 (en) Compositions and procedure for treating sclerosis multiplex
GB9422571D0 (en) Haemorrihoidal compositions and method of use
IL129138A0 (en) Methods and compositions for immunomodulation
IL127446A0 (en) Compositions and methods for coating medical devices
EP0874828A4 (en) Composition for treating pain
GB9415421D0 (en) Cosmetic compositions and processes for manufacture thereof
EP0703282A3 (en) Composition for surface treatment
PL317197A1 (en) Compositions for and method of treating sclerosis multiplex
ZA9510792B (en) Polymerization compounds and compositions
GB9624501D0 (en) Insecticial compositions and method
GB9405229D0 (en) Compositions of matter
IL111554A0 (en) Methods and compositions for hair treatment
GB9415420D0 (en) Cosmetic compositions and processes for manufacture thereof
IL112564A0 (en) 1-beta-methyl-carbapenems and compositions containing them
EP0835092A4 (en) Composition and treatment for baldness
HU9701150D0 (en) Composition for preventing and treating disturbances of vision
IL124419A0 (en) Composition for treating pain
GB9508546D0 (en) Method and composition
PL314588A1 (en) Application of pentoxyphyline in treatment of sclerosis multiplex
GB9419087D0 (en) Method and composition
GB9414888D0 (en) Method and composition
IL113444A0 (en) Compositions and methods for treating leukemia
GB9416340D0 (en) Oil treatment and compositions therefor
ZA953730B (en) Compositions and treatment for multiple sclerosis
ZA959033B (en) Composition and treatment for multiple sclerosis